# Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

> **NCT01170065** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 198 (actual)

## Conditions studied

- Pulmonary Fibrosis

## Interventions

- **DRUG:** BIBF 1120
- **DRUG:** BIBF 1120
- **DRUG:** BIBF 1120
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01170065
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-25
- **Primary completion:** 2016-09-26
- **Final completion:** 2016-09-26
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170065, "Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01170065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*